MaxCyte to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MaxCyte, a leader in cell-engineering technology, announced its participation in several upcoming virtual investor conferences. Key events include the BIO CEO & Investor Conference on February 15, the BTIG MedTech event on February 17 at 3:00 p.m. ET, and the Cowen Annual Healthcare Conference on March 7 at 9:50 a.m. ET. The company will provide live and archived webcasts of these presentations on its investor relations website. MaxCyte's technologies aim to enhance cell-based research and support the growing cell therapy market.

GAITHERSBURG, Md., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following virtual investor conferences:

• BIO CEO & Investor Conference
  Presentation on Tuesday, February 15^th

• BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
  Fireside chat on Thursday, February 17^th at 3:00 p.m. Eastern Time

• Cowen Annual Healthcare Conference
  Fireside chat on Monday, March 7^th at 9:50 a.m. Eastern Time

Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400 ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 maxcyte@consilium-comms.com

FAQ

What investor conferences is MaxCyte participating in February 2022?

MaxCyte is participating in the BIO CEO & Investor Conference on February 15 and the BTIG MedTech Conference on February 17, 2022.

When will MaxCyte's fireside chat at the Cowen Annual Healthcare Conference take place?

MaxCyte's fireside chat at the Cowen Annual Healthcare Conference is scheduled for March 7, 2022, at 9:50 a.m. ET.

Where can I find webcasts of MaxCyte's investor presentations?

Live and archived webcasts of MaxCyte's presentations will be available on their investor relations website.

What is the focus of MaxCyte's technologies?

MaxCyte's technologies focus on advancing innovative cell-based research and the development of next-generation cell therapies.

What is the ticker symbol for MaxCyte?

MaxCyte trades under the ticker symbol MXCT on NASDAQ.